PT3151831T - Ativação de células cancerígenas com uma dose baixa de naltrexona - Google Patents

Ativação de células cancerígenas com uma dose baixa de naltrexona

Info

Publication number
PT3151831T
PT3151831T PT15730526T PT15730526T PT3151831T PT 3151831 T PT3151831 T PT 3151831T PT 15730526 T PT15730526 T PT 15730526T PT 15730526 T PT15730526 T PT 15730526T PT 3151831 T PT3151831 T PT 3151831T
Authority
PT
Portugal
Prior art keywords
cancerigenal
cell activation
naltrexone dose
low
low naltrexone
Prior art date
Application number
PT15730526T
Other languages
English (en)
Portuguese (pt)
Inventor
Dalgleish Angus
Liu Wai
Original Assignee
Ldn Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ldn Pharma Ltd filed Critical Ldn Pharma Ltd
Publication of PT3151831T publication Critical patent/PT3151831T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT15730526T 2014-06-09 2015-06-09 Ativação de células cancerígenas com uma dose baixa de naltrexona PT3151831T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1410216.4A GB201410216D0 (en) 2014-06-09 2014-06-09 Therapeutic

Publications (1)

Publication Number Publication Date
PT3151831T true PT3151831T (pt) 2019-06-18

Family

ID=51266919

Family Applications (1)

Application Number Title Priority Date Filing Date
PT15730526T PT3151831T (pt) 2014-06-09 2015-06-09 Ativação de células cancerígenas com uma dose baixa de naltrexona

Country Status (10)

Country Link
US (3) US11065245B2 (enExample)
EP (1) EP3151831B1 (enExample)
JP (1) JP6620338B2 (enExample)
DK (1) DK3151831T3 (enExample)
ES (1) ES2730348T3 (enExample)
GB (1) GB201410216D0 (enExample)
PL (1) PL3151831T3 (enExample)
PT (1) PT3151831T (enExample)
TR (1) TR201908660T4 (enExample)
WO (1) WO2015189597A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201308440D0 (en) * 2013-05-10 2013-06-19 Dalgleish Angus Therapeutic
EP3416619A2 (en) * 2016-02-18 2018-12-26 Immune Therapeutics, Inc. Method for inducing a sustained immune response
GB201704909D0 (en) 2017-03-28 2017-05-10 Ldn Pharma Ltd Cancer therapy
GB201704911D0 (en) * 2017-03-28 2017-05-10 Ldn Pharma Ltd High dose combo I
GB201704913D0 (en) 2017-03-28 2017-05-10 Ldn Pharma Ltd Method
EP3482751A1 (en) 2017-11-14 2019-05-15 LDN Pharma Limited Cancer treatment
JP7502320B2 (ja) * 2019-03-06 2024-06-18 エルディーエヌ ファーマ リミテッド 効力を判定するための方法
WO2020178446A1 (en) * 2019-03-06 2020-09-10 LDN Pharma Limited Method of monitoring treatment
GB201903546D0 (en) * 2019-03-15 2019-05-01 Ldn Pharma Ltd Cancer treatment
JP2022541452A (ja) 2019-07-15 2022-09-26 ロバクサ がんの治療のための方法および組成物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030144312A1 (en) * 2001-10-30 2003-07-31 Schoenhard Grant L. Inhibitors of ABC drug transporters in multidrug resistant cancer cells
CA2719134C (en) 2008-03-21 2015-06-30 The University Of Chicago Treatment with opioid antagonists and mtor inhibitors
JP2015107918A (ja) 2012-02-14 2015-06-11 国立研究開発法人国立がん研究センター 抗がん剤の作用を増強する医薬組成物、がん治療用キット、診断薬、及びスクリーニング方法
GB201308440D0 (en) * 2013-05-10 2013-06-19 Dalgleish Angus Therapeutic

Also Published As

Publication number Publication date
JP6620338B2 (ja) 2019-12-18
PL3151831T3 (pl) 2021-05-31
GB201410216D0 (en) 2014-07-23
US20250032481A1 (en) 2025-01-30
US20170119755A1 (en) 2017-05-04
EP3151831B1 (en) 2019-03-13
TR201908660T4 (en) 2019-07-22
US12144807B2 (en) 2024-11-19
EP3151831A1 (en) 2017-04-12
US20210308125A1 (en) 2021-10-07
DK3151831T3 (da) 2019-06-24
WO2015189597A1 (en) 2015-12-17
JP2017519006A (ja) 2017-07-13
US11065245B2 (en) 2021-07-20
ES2730348T3 (es) 2019-11-11

Similar Documents

Publication Publication Date Title
IL274903A (en) cell
GB2585814B (en) Right angle time-of-flight detector with an extended life time
GB201518817D0 (en) Cell
SG11201608972WA (en) Auto-injector with indicator
GB2528078B (en) Structure
GB201412161D0 (en) Structure
FR3024228B1 (fr) Structure deployable a metre-ruban
SG11201610831PA (en) Lithium-sulphur battery
GB2522522B (en) Structure
DK3340968T3 (da) Implanterbare naltrexon-tabletter
DK3177838T3 (en) Fluid-redirecting structure
IL249801B (en) Panel equipped with a photovoltaic device
IL246051A0 (en) Powdery, musky odorant macrocycles
SG11201506911QA (en) Primer technology
ZA201800972B (en) Methanogenesis
GB201418068D0 (en) Polymer
GB201402404D0 (en) Polymer
PL3149792T3 (pl) Ogniwo litowo-siarkowe
HUE045894T2 (hu) Telep szenzorral
PT2910223T (pt) Emplastro com dispensador de medicação
GB201410517D0 (en) Foil structure
GB201411985D0 (en) Battery
HU4618U (en) With ozonegas functioning germ-killer device
UA30460S (uk) Акумуляторна батарея
TH1501006426A (th) เครื่องปฏิกรณ์ที่มีชุดส่องสว่างแบบรวมเป็นหน่วยเดียวกัน